CA
NZ
UK
AU
IND
US
● Aldeyra Therapeutics closed at $1.17 on Friday, October 2, 2026, a decline of 9.30% on the session.
● No clinical-trial result, regulatory decision, financing,Partnershipor analyst action could be tied to the session.
● NoEarningsrelease,Businessupdate,Acquisitionor analyst action could be tied to the session.
● BioStem Technologies closed at $2.73 on Friday, October 2, 2026, a decline of 11.07% on the session.
● MSP Recovery's shares began trading on the OTCQB market on December 23, 2025, afterNasdaqmoved to delist the company.
● Panbela moved fromNasdaqto the OTCQB on April 17, 2024, after missing the minimum stockholders'Equityrequirement.
●Nasdaqremoved Virpax in 2025 for missing the minimum stockholders'Equityrequirement, and the company would not appeal.
● Biodexa received $2.3 million in gross proceeds from aWarrantexercise on September 15, 2026, alongside going-concern warnings.
BioMarin (NASDAQ:BMRN), the San Rafael, California rare disease drugmaker founded in 1997 andMarketingnine therapies, is slipping in Friday's session even after presenting five-year Phase 3 extension data for Pombiliti plus Opfolda in late-onset Pompe disease at the World Muscle Society Congress. The shares are …
GRAIL (NASDAQ:GRAL), the Menlo Park, California company behind the Galleri blood test that screens asymptomatic adults over 50 for multiple cancers, is rebounding in Friday's session after a sharp pullback in the prior session. The shares are up 6.73% at $141.48, while the healthcare …
Please wait processing your request...